Top 5 Heal Care Companies For 2015

Top 5 Heal Care Companies For 2015: Orexigen Therapeutics Inc.(OREX)

Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed phase III clinical trials; and Empatic that has completed phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; and naltrexone is a treatment for alcohol and opioid addiction. The company?s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide is for the adjunctive treatment of partial seizures, a form of epilepsy. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave. Orexigen Therapeutics, Inc. was founded in 2002 and is based in La Jolla, California.

Advisors' Opinion:

• [By John Udovich]

  Orexigen Therapeutics, Inc (NASDAQ: OREX), like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS), is a speculative small cap obesity drug stock that has the potential for coming up with the next big thing in the treatment of obesity that is increasingly a global problems. I should mention that we have recently added Orexigen Therapeutics to our SmallCap Network Elite Opportunity (SCN EO) portfolio as an extremely speculative biotech bet because its lead obesity drug candidate has the potential to be approved by September 11th of this year.

• [By Monica Gerson]

  Orexigen Therapeutics (NASDAQ: OREX) is estimated to post a Q4 loss at $0.19 per share on revenue of $900.00 thousand.

  Delcath Systems (NASDAQ: DCTH) is expected to post a Q4 loss at $0.05 per share on revenue ! of $100.00 thousand.

• [By James Brumley]

  But, given the pharma industry’s migration towards this more potent class of medicines, MNTA stock has plenty working in its favor for the long haul.

  Orexigen Therapeutics (OREX)

  Think Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) used up all weight loss drug enthusiasm when the two companies won approval for Belviq and Qsymia, respectively, back in 2012?

• [By Sean Williams]

  These might not be household names in the U.S., but they do brandish global licensing partnerships with companies that might be more familiar to you. Takeda, for example, has licensing agreements in place with Orexigen Therapeutics (NASDAQ: OREX  ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN  ) with regard to FDA-approved Hodgkin lymphoma drug Adcetris. 

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-heal-care-companies-for-2015.html